Endomorphin-2

Endomorphin-2 is concentrated in spinal cord dorsal horn laminae I, II, and V -- the primary sites for nociceptive processing. Presynaptic MOR on C-fiber and A-delta terminals are activated by EM-2, inhibiting substance P and glutamate release. Postsynaptic MOR on projection neurons are hyperpolarized. This laminar specificity makes EM-2 a powerful tool for studying spinal pain circuitry.

MOR receptors on peripheral sensory neurons are upregulated during inflammation. EM-2 administration directly into inflamed tissue (intraplantar injection) produces peripheral analgesia without CNS penetration, validating peripheral MOR as a drug target free of CNS side effects. This peripheral specificity is particularly relevant for inflammatory pain states where peripheral MOR is highly expressed.

EM-2 in the spinal dorsal horn modulates visceral nociception from colorectal distension and colitis models. Spinally administered EM-2 reduces visceromotor responses to colorectal distension in IBS-like models. The gut-spinal cord axis involving EM-2 represents a target for IBS and inflammatory bowel pain management.

EM-2 in inflamed tissue activates peripheral MOR, producing analgesia without CNS exposure. Mast cells and T lymphocytes in inflamed tissue contain EM-2 and release it upon stimulation, creating local opioid analgesia. Peripherally restricted EM-2 analogs could provide anti-inflammatory analgesia without addiction risk.

Repeated intrathecal EM-2 produces tolerance more slowly than morphine in some protocols. The distinct binding mode at MOR (Phe at position 3 vs Trp in EM-1, vs morphine) produces different desensitization profiles. EM-2 preferentially activates Gi over beta-arrestin2 in some assays, predicting reduced tolerance development, though direct comparisons with morphine are complex.